Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients.

Molica M, Miralles G, Dillon R, Annunziata M, Basheer F, Bergua JM, Calmet FV, Campbell V, Cetin D, Cimino G, Ciotti G, Corbingi A, De Fazio L, Erol HA, Federico V, Gil C, Mutlu YG, Malcorra AB, Mariani S, Mazzone C, Mulè A, Musuraca G, Khan A, Norata M, O'Nions J, Palumbo FE, Papayannidis C, Piccioni AL, Rubio MTO, Sanchez-Tovar J, Serin I, Serrao A, Sevindik OG, Sucato G, Urbano MA, Vetro C, Vives S, Rossi M, Martelli MP, Montesinos P, Othman J, Perrone S

Open source

DOI: 10.1002/ajh.70142
Published: 2026 Jan
Container: American journal of hematology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/ajh.70142,
  title = {Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients.},
  author = {Molica M and Miralles G and Dillon R and Annunziata M and Basheer F and Bergua JM and Calmet FV and Campbell V and Cetin D and Cimino G and Ciotti G and Corbingi A and De Fazio L and Erol HA and Federico V and Gil C and Mutlu YG and Malcorra AB and Mariani S and Mazzone C and Mulè A and Musuraca G and Khan A and Norata M and O'Nions J and Palumbo FE and Papayannidis C and Piccioni AL and Rubio MTO and Sanchez-Tovar J and Serin I and Serrao A and Sevindik OG and Sucato G and Urbano MA and Vetro C and Vives S and Rossi M and Martelli MP and Montesinos P and Othman J and Perrone S},
  year = {2026},
  journal = {American journal of hematology},
  doi = {10.1002/ajh.70142},
  url = {https://doi.org/10.1002/ajh.70142}
}

RIS

TY  - JOUR
TI  - Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients.
AU  - Molica M
AU  - Miralles G
AU  - Dillon R
AU  - Annunziata M
AU  - Basheer F
AU  - Bergua JM
AU  - Calmet FV
AU  - Campbell V
AU  - Cetin D
AU  - Cimino G
AU  - Ciotti G
AU  - Corbingi A
AU  - De Fazio L
AU  - Erol HA
AU  - Federico V
AU  - Gil C
AU  - Mutlu YG
AU  - Malcorra AB
AU  - Mariani S
AU  - Mazzone C
AU  - Mulè A
AU  - Musuraca G
AU  - Khan A
AU  - Norata M
AU  - O'Nions J
AU  - Palumbo FE
AU  - Papayannidis C
AU  - Piccioni AL
AU  - Rubio MTO
AU  - Sanchez-Tovar J
AU  - Serin I
AU  - Serrao A
AU  - Sevindik OG
AU  - Sucato G
AU  - Urbano MA
AU  - Vetro C
AU  - Vives S
AU  - Rossi M
AU  - Martelli MP
AU  - Montesinos P
AU  - Othman J
AU  - Perrone S
PY  - 2026
JO  - American journal of hematology
DO  - 10.1002/ajh.70142
UR  - https://doi.org/10.1002/ajh.70142
ER  -

APA

M, M., G, M., R, D., M, A., F, B., JM, B., FV, C., V, C., D, C., G, C., G, C., A, C., L, D. F., HA, E., V, F., C, G., YG, M., AB, M., S, M., C, M., A, M., G, M., A, K., M, N., J, O., FE, P., C, P., AL, P., MTO, R., J, S., I, S., A, S., OG, S., G, S., MA, U., C, V., S, V., M, R., MP, M., P, M., J, O., & S, P. (2026). Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients.. American journal of hematology. https://doi.org/10.1002/ajh.70142

Source records

pubmed · retrieved 2026-09-25T06:35:01.187Z